Retrospective Cohort Study
Copyright ©The Author(s) 2022.
World J Gastrointest Endosc. Dec 16, 2022; 14(12): 759-768
Published online Dec 16, 2022. doi: 10.4253/wjge.v14.i12.759
Table 1 Patient background before and after propensity score matching
Before propensity score matching
After propensity score matching
Early group (< 24 h)
Elective group (≥ 24 h)
SMD
Early group (< 24 h)
Elective group (≥ 24 h)
SMD
Variables
n = 328
n = 226

n = 191
n = 191

Age, yr, median (IQR)79.0 (71.0–84.0)79.0 (72.3–84.0)0.04778.0 (70.0–84.0)79.0 (71.5–84.0)0.057
Male, n (%)220 (67.1) 135 (59.7) 0.153132 (69.1) 126 (66.0) 0.067
Body mass index, n (%)0.0870.094
< 18.546 (14.0) 18 (8.0) 15 (7.9) 18 (9.4)
18.5-24.9210 (64.0) 153 (67.7) 124 (64.9) 128 (67.0)
25-29.976 (23.2) 76 (23.2) 45 (23.6) 39 (20.4)
≥ 3012 (3.7) 9 (4.0) 3 (1.6) 4 (2.1)
Smoking0.1620.075
Current, n (%)45 (13.7) 25 (11.1) 23 (12.0) 24 (12.6)
Past, n (%)104 (31.7) 64 (28.3) 64 (33.5) 58 (30.4)
Never, n (%)169 (51.5) 133 (58.8) 101 (52.9) 105 (55.0)
No information, n (%)10 (3.0) 4 (1.8) 3 (1.6) 4 (2.1)
Performance status ≥ 3, n (%)34 (10.4) 20 (8.8) 0.05115 (7.9) 20 (10.5) 0.091
Comorbidities
Hypertension, n (%)210 (64.0) 152 (67.3) 0.051124 (64.9) 122 (63.9) 0.022
Diabetes mellitus, n (%)67 (20.4) 51 (22.6) 0.05241 (21.5) 37 (19.4) 0.052
Coronary artery disease, n (%)92 (28.0) 67 (29.6) 0.03563 (33.0) 57 (29.8) 0.068
Chronic kidney disease, n (%)33 (10.1) 28 (12.4) 0.07422 (11.5) 25 (13.1) 0.048
Hemodialysis, n (%)2 (0.6) 5 (2.2) 0.1362 (1.0) 4 (2.1) 0.084
Medication
Antithrombotics, n (%)123 (37.5) 80 (35.4) 0.04479 (41.4) 68 (35.6) 0.119
NSAIDs, n (%)14 (4.3) 14 (6.2) 0.0878 (4.2) 9 (4.7) 0.025
Shock vitality at presentation, n (%)28 (8.5) 12 (5.3) 0.1279 (4.7) 12 (6.3) 0.069
Contrast CT findings0.8110.027
With an extravascular leak, n (%)129 (39.3) 17 (7.5) 17 (8.9) 17 (8.9)
Without an extravascular leak, n (%)159 (48.5) 170 (75.2) 138 (72.3) 140 (73.3)
Without contrast CT, n (%)40 (12.2) 39 (17.3) 36 (18.8) 34 (17.8)
Blood sampling data
Hemoglobin < 10 g/dL, n (%)84 (25.6) 61 (27.0) 0.03154 (28.3) 51 (26.7) 0.035
Platelet < 10000 /μL, n (%)4 (1.2) 3 (1.3) 0.012 (1.0) 2 (1.0) < 0.001
Table 2 Outcomes of the main analysis
Outcomes
Early group (< 24 h)
Elective group (≥ 24 h)
Difference (95%CI)
P value
Primary outcome
Length of hospital stay, days, median (IQR)7 (7–9)8 (7– 9.5)0.10
Secondary outcomes
Identification of stigmata of recent hemorrhage (%)32.5 (62/191)20.9 (40/191)11.6 (2.7 to 20.3)0.02
Rebleeding (%)28.8 (55/191) 24.1 (46/191) 4.7 (-4.1 to 13.5)0.35
Red blood cell transfusion ≥ 4 units (%)29.3 (56/191) 27.7 (53/191) 1.6 (-7.5 to 10.6)0.82
Interventional radiology and abdominal surgery (%)2.1 (4/191)1.6 (3/191)0.5 (-2.2 to 3.2)1.00
Table 3 Results of sensitivity analysis for a colonoscopy exposure time of 12 h
Outcomes
Early group (< 12 h)
Elective group (≥ 12 h)
Difference (95%CI)
P value
Primary outcome
Length of hospital stay, median (IQR)7 (6–9)8 (7– 9)0.09
Secondary outcomes
Identification of stigmata of recent hemorrhage (%)40.8 (51/125)33.6 (42/125)7.2 (-4.7 to 19.1)0.30
Rebleeding (%)37.6 (47/125) 25.6 (32/125) 12.0 (0.6 to 23.4)0.06
Red blood cell transfusion ≥ 4 units (%)30.4 (38/125) 28.8 (36/125) 1.6 (-9.7 to 12.9)0.89
Interventional radiology and abdominal surgery (%)2.4 (3/125)3.2 (4/125)-0.8 (-4.9 to 3.3)0.74
Table 4 Results of sensitivity analysis using multivariate analysis
Primary outcomeCoefficient (95%CI)P value
Length of hospital stay0.08 (-0.71 to 0.87)0.84
Secondary outcomesOdds ratio (95%CI)P value
Identification of stigmata of recent hemorrhage1.76 (1.14–2.70)0.01
Rebleeding1.21 (0.78–1.86)0.39
Red blood cell transfusion ≥ 4 units 0.91 (0.55–1.50)0.71
Interventional radiology and abdominal surgery 0.93 (0.23–3.78)0.92
Table 5 Different hemostatic methods in the main analysis
Hemostatic method
Early group (< 24 h)
Elective group (≥ 24 h)
P value
Direct clipping method, n (%)17/60 (28.3)9/40 (22.5)0.794
Zipper clipping, method, n (%)30/60 (50.0)21/40 (52.5)
Endoscopic band ligation method, n (%)13/60 (21.7)10/40 (25.0)
Table 6 Rebleeding rates by hemostatic methods, n (%)
Hemostatic method
Direct clipping method (n = 43)
Zipper clipping method (n = 82)
Endoscopic band ligation method (n = 47)
Rebleeding4 (9.3)37 (45.1) 5 (10.6)